Table 3 Comparison of demographic, clinical data and pathological data and VEGF levels in patients according to genotyping of VEGFA −634G/C (rs2010963) polymorphism
|  | Patients with CC genotype (n = 37) | Patients with CG genotype (n = 20) | Patients with GG genotype (n = 13) | P |
|---|---|---|---|---|
Age (mean ± SD) | 55.76 ± 7.7 | 53.8 ± 8.1 | 52.5 ± 7.2 | P = 0.39* |
Sex | ||||
 Male (N0(%)) | 11 (29.7%) | 5 (25%) | 5 (38.5%) | P = 0.71** |
 Female (N0(%)) | 26 (70.3%) | 15 (75%) | 8 (61.5%) | |
Clinical Stages | ||||
 I (N0(%)) | 26 (70.3%) | 2 (10%) | 2 (15.4%) | P = 0.0001** |
 II (N0(%)) | 9 (24.3%) | 11 (55%) | 10 (76.9%) | |
 III (N0(%)) | 1 (29.7%) | 7 (35%) | 1 (7.7%) | |
Size of the tumor (N0(%)) | ||||
 ≤ 2 cm | 11 (29.7%) | 7 (35%) | 3 (23.1%) | P = 0.73** |
 > 2-4 cm | 17 (45.9%) | 11 (55%) | 7 (53.8%) | |
 > 4 cm | 9 (24.3%) | 2 (10%) | 3 (23.1%) | |
Pathological classification (N0(%)) | ||||
 Papillary carcinoma | 36 (79.3%) | 19 (95%) | 11 (84.6%) | P = 0.24** |
 Follicular carcinoma | 1 (2.7%) | 1 (15%) | 2 (15.4%) | |
VEGF pg/ml (mean ± SD) | 1061.054 ± 163.25 | 1295.9 ± 68.74 | 1533.08 ± 109.95 | P = 0.001* |